Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Feb;8(2):304-13.
doi: 10.18632/aging.100896.

Inhalational Alzheimer's disease: an unrecognized - and treatable - epidemic

Dale E Bredesen  1   2
Affiliations
Case Reports

Inhalational Alzheimer's disease: an unrecognized - and treatable - epidemic

Dale E Bredesen. Aging (Albany NY). 2016 Feb.

Abstract

Alzheimer's disease is one of the most significant healthcare problems today, with a dire need for effective treatment. Identifying subtypes of Alzheimer's disease may aid in the development of therapeutics, and recently three different subtypes have been described: type 1 (inflammatory), type 2 (non-inflammatory or atrophic), and type 3 (cortical). Here I report that type 3 Alzheimer's disease is the result of exposure to specific toxins, and is most commonly inhalational (IAD), a phenotypic manifestation of chronic inflammatory response syndrome (CIRS), due to biotoxins such as mycotoxins. The appropriate recognition of IAD as a potentially important pathogenetic condition in patients with cognitive decline offers the opportunity for successful treatment of a large number of patients whose current prognoses, in the absence of accurate diagnosis, are grave.

Keywords: biomarkers; biotoxins; chronic inflammatory response syndrome; cognition; dementia; mycotoxins; neurodegeneration.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

The author of this manuscript declares no conflict of interest.

References

    1. James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA. Contribution of Alzheimer disease to mortality in the United States. Neurology. 2014;82:1045–1050. - PMC - PubMed
    1. Seshadri S, Drachman DA, Lippa CF. Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. Arch Neurol. 1995;52:1074–1079. - PubMed
    1. Bredesen DE. Reversal of cognitive decline: A novel therapeutic program. Aging (Albany NY) 2014;6:1–11. - PMC - PubMed
    1. Bredesen DE. Metabolic profiling distinguishes three subtypes of Alzheimer's disease. Aging (Albany NY) 2015;7:595–600. - PMC - PubMed
    1. Shoemaker RT., MD . Surviving mold: life in the era of dangerous buildings. Baltimore, MD: Otter Bay Books; 2010.

Publication types

Supplementary concepts